Trial Profile
A Multicenter, Prospective, Observational, Non-Interventional Study Evaluating the Efficacy and Safety of Using Tocilizumab (TCZ) for Confirmed Rheumatoid Arthritis (RA) Patients In Clinical Practice
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 17 Oct 2018 Status changed from recruiting to discontinued.
- 12 Jul 2017 Status changed from not yet recruiting to recruiting.
- 04 May 2016 Planned End Date changed from 1 Dec 2019 to 1 Jul 2018.